Tags

Type your tag names separated by a space and hit enter

Identification of critical pathways and hub genes in TP53 mutation prostate cancer by bioinformatics analysis.

Abstract

Aim:

The TP53 mutant is one of the most common mutant genes in prostate cancer. Materials & methods: The RNA-seq data of prostate cancer was downloaded from TCGA database. Gene set and enrichment analyses were done by online tools.

Results:

TP53 mutation was found in 18% prostate cancer patients. Enrichment analysis indicated that differentially expressed genes were enriched in G-protein-coupled receptor signaling pathways, cell growth and metabolism. The top ten hub genes were identified. Further analysis showed increased risk of recurrence, lower TP53 mRNA level and higher Gleason scores in patients with TP53 mutation.

Conclusion:

Our results suggest that multiple genes and pathways may play key roles in TP53 mutant prostate cancer, providing candidate targets and strategies for individualized treatment.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, 215000, PR China.

    ,

    Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, 215000, PR China.

    ,

    Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, 215000, PR China.

    ,

    Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, 215000, PR China.

    ,

    Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, 215000, PR China.

    ,

    Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, 215000, PR China.

    Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, 215000, PR China.

    Source

    Biomarkers in medicine : 2019 May 22 pg

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    31116024

    Citation

    Sun, Jian, et al. "Identification of Critical Pathways and Hub Genes in TP53 Mutation Prostate Cancer By Bioinformatics Analysis." Biomarkers in Medicine, 2019.
    Sun J, Zhang K, Cai Z, et al. Identification of critical pathways and hub genes in TP53 mutation prostate cancer by bioinformatics analysis. Biomark Med. 2019.
    Sun, J., Zhang, K., Cai, Z., Li, K., Zhao, C., Fan, C., & Wang, J. (2019). Identification of critical pathways and hub genes in TP53 mutation prostate cancer by bioinformatics analysis. Biomarkers in Medicine, doi:10.2217/bmm-2019-0141.
    Sun J, et al. Identification of Critical Pathways and Hub Genes in TP53 Mutation Prostate Cancer By Bioinformatics Analysis. Biomark Med. 2019 May 22; PubMed PMID: 31116024.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Identification of critical pathways and hub genes in TP53 mutation prostate cancer by bioinformatics analysis. AU - Sun,Jian, AU - Zhang,Ke, AU - Cai,Zheng, AU - Li,Kai, AU - Zhao,Chunchun, AU - Fan,Caibin, AU - Wang,Jianqing, Y1 - 2019/05/22/ PY - 2019/5/23/entrez KW - RNA sequencing KW - TCGA KW - TP53 mutation KW - bioinformatics analysis KW - prostate cancer JF - Biomarkers in medicine JO - Biomark Med N2 - Aim: The TP53 mutant is one of the most common mutant genes in prostate cancer. Materials & methods: The RNA-seq data of prostate cancer was downloaded from TCGA database. Gene set and enrichment analyses were done by online tools. Results: TP53 mutation was found in 18% prostate cancer patients. Enrichment analysis indicated that differentially expressed genes were enriched in G-protein-coupled receptor signaling pathways, cell growth and metabolism. The top ten hub genes were identified. Further analysis showed increased risk of recurrence, lower TP53 mRNA level and higher Gleason scores in patients with TP53 mutation. Conclusion: Our results suggest that multiple genes and pathways may play key roles in TP53 mutant prostate cancer, providing candidate targets and strategies for individualized treatment. SN - 1752-0371 UR - https://www.unboundmedicine.com/medline/citation/31116024/Identification_of_critical_pathways_and_hub_genes_in_TP53_mutation_prostate_cancer_by_bioinformatics_analysis L2 - http://www.futuremedicine.com/doi/full/10.2217/bmm-2019-0141?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -